A Phase 1 interventional study of [14C]-LY3549492 and LY3549492 in Healthy Male, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-28.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 ([14C] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive [14C] LY3549492 given into a vein.
The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath.
The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Carbon-14-Labeled \[14C\]-LY3549492 administered as oral solution.
Drug: [14C]-LY3549492
LY3549492 administered as oral solution followed 3 hours later by \[14C\] LY3549492 will be administered as intravenous (IV) infusion.
Drug: LY3549492 · Drug: [14C]-LY3549492
Administered as oral solution.
Administered orally.
Administered as IV infusion.
Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A
Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose
Time frame: Predose up to Day 24 postdose in Part A
Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part A
Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total
Time frame: Predose up to Day 24 postdose in Part A
Pharmacokinetic (PK): Area Under the Curve (AUC) for Oral Determination of Absolute Bioavailability (F) of LY3549492 in Part B
PK: AUC for oral determination of absolute bioavailability (F) of LY3549492
Time frame: Predose up to Day 7 postdose in Part B
PK: AUC for Intravenous (IV) Determination of Absolute Bioavailability (F) of LY3549492 in Part B
PK: AUC for IV determination of absolute bioavailability (F) of LY3549492
Time frame: Predose up to Day 7 postdose in Part B
PK: Area Under the Concentration (AUC) for Radioactivity in Plasma and Whole Blood in Part A
PK: AUC for radioactivity
Time frame: Predose up to Day 24 postdose in Part A
PK: Maximum Concentration (Cmax) for Radioactivity in Plasma and Whole Blood in Part A
PK: Cmax for radioactivity
Time frame: Predose up to Day 24 postdose in Part A
PK: AUC of LY3549492 in Plasma in Part A
PK: AUC of LY3549492 in plasma
Time frame: Predose up to Day 24 postdose in Part A
PK: Cmax of LY3549492 in Plasma in Part A
PK: Cmax of LY3549492 in plasma
Time frame: Predose up to Day 24 postdose in Part A
Total Radioactivity Recovered in Urine, Feces, and Expired Air (if applicable) in Part A
Total radioactivity recovered in urine, feces, and expired air (if applicable) in Part A
Time frame: Predose up to Day 24 postdose in Part A
Total Number of Metabolites and Identification of Metabolites of LY3549492 in Part A
Total number of metabolites and identification of metabolites of LY3549492
Time frame: Predose up to Day 24 postdose in Part A
PK: AUC of LY3549492, [14C]-LY3549492, and Total Radioactivity in Plasma in Part B
AUC of LY3549492, \[14C\]-LY3549492, and total radioactivity in plasma in Part B
Time frame: Predose up to Day 7 postdose in Part B
PK: Cmax of LY3549492, [14C]-LY3549492, and Total Radioactivity in Plasma in Part B
Cmax of LY3549492, \[14C\]-LY3549492, and total radioactivity in plasma in Part B
Time frame: Predose up to Day 7 postdose in Part B
Total Radioactivity Recovered in Urine and Feces in Part B
Total radioactivity recovered in urine and feces in Part B
Time frame: Predose up to Day 7 postdose in Part B
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2024 to primary completion in Feb 2024, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naperiglipron